SEC Form 4 · accession 0001562180-17-001139
PROGENICS PHARMACEUTICALS INC · PGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Robert Baker
Officer — Chief Executive Officer · Director
Period of report
Mar 1, 2017
Accepted (ET)
Mar 7, 2017 · 11:37 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000835887
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (Right to Buy)F1 | $11.32 | Mar 1, 2017 | A | 175,000 | A | — | Mar 1, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F13yr 33% On Vest beginning on 01-Mar-2017